FierceMarkets

FierceMarkets
Share

FierceMarkets

 •  December 28, 2017

A Fresenius Kabi cancer drug plant in India savaged by the FDA in the past for hiding serious drug testing issues has been branded with a new warning letter. The letter to the oncology API plant in Kalyani, Nadia, West Bengal, was issued earlier this month and posted by the FDA this week. While only two observations are outlined in the letter, the...

FierceMarkets

 •  December 27, 2017

Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller. The company Tuesday agreed to shell out $18 per share for Sucampo and its debt, bringing the deal’s total value to about $1.2 billion. The takeover pact boosted shares of Mallinckrodt, which as of Friday were down 53% for the...

FierceMarkets

 •  December 21, 2017

Disasters, both natural and manmade, wreaked havoc on pharma supply chains this year, exposing vulnerabilities and costing the industry hundreds of millions, if not billions, of dollars. Hurricanes took out power and plants in Puerto Rico, creating or exacerbating shortages of IV products that drugmakers, hospitals and the FDA will be dealing with...

FierceMarkets

 •  December 20, 2017

When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need. To create this forecast, it must factor in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Variations in any one of...

FierceMarkets

 •  December 20, 2017

Thanks for the advice, but no thanks. That's what Teva told Israeli officials Tuesday after Prime Minister Benjamin Netanyahu encouraged the debt-laden drugmaker to keep open its manufacturing facility in Jerusalem in the wake of last week’s announcement of stunning cuts worldwide. In a meeting at the prime minister's office in Jerusalem, Teva CEO...

FierceMarkets

 •  December 14, 2017

Teva’s layoffs and cost cuts are here—and they're far larger than reports predicted. The company said Thursday it would slash its headcount by 14,000, eliminating more than 25% of its worldwide workforce. That's 4,000 more than the most dire scenario raised ahead of the announcement. It's aiming to cut $3 billion from its annual costs, $1 billion...

FierceMarkets

 •  December 14, 2017

Pharma investors may favor price hikes if the tactic means sales, profits and stock prices climb. But wary members of the Interfaith Center on Corporate Responsibility see things differently, and they're pushing several top drugmakers to review whether their executive pay contributes to high drug prices. As investors in AbbVie, Amgen, Biogen,...

FierceMarkets

 •  December 11, 2017

It’s no secret that Teva’s about to unveil some major layoffs. And the tally could reportedly reach 10,000. That’s the figure cited by Bloomberg, whose sources said the company is looking to pare down expenses by $1.5 billion to $2 billion over the next two years. A little less than half of the job cuts would be tied to R&D spending. Plans could...

FierceMarkets

 •  December 6, 2017

Years after suing drug giant Merck & Co. for serious injuries allegedly caused by osteoporosis drug Fosamax, more than 500 plaintiffs will have to wait to hear the U.S. Solicitor General's take on their case, and the outcome could reverberate across the pharmaceutical industry. That's because Merck's bid at the U.S. Supreme Court seeks to...

FierceMarkets

 •  December 5, 2017

Depomed is selling off the franchise that was once the center of its growth hopes, and plenty of the company's employees are leaving with it. Less than three years after shelling out $1.05 billion to acquire Nucynta ER and XR from Johnson & Johnson, the California drugmaker has licensed the meds to Collegium Pharmaceutical for just $10 million...